Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNovacyt Regulatory News (NCYT)

Share Price Information for Novacyt (NCYT)

Share Price is delayed by 15 minutes
Get Live Data
41.50    0.00 (0.00%)
Bid:
41.00
Ask:
42.90
Spread: 1.90 (4.634%)
Market Cap: £30.06m
NCYT Live PriceLast checked at - London Stock Exchange

Intraday Novacyt Share Chart

AGM Voting

13 Jun 2022 07:00

RNS Number : 5630O
Novacyt S.A.
13 June 2022
 

 

 

Novacyt S.A.

 

("Novacyt", the "Company" or the "Group")

 

AGM voting

 

Paris, France and Camberley, UK - 13 June 2022 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, will be holding its annual general meeting (AGM) as an open online meeting at 2pm CEST/1pm BST on 21 June 2022. As usual, and in accordance with French corporate law, the AGM comprises both ordinary and extraordinary general meetings.

 

Under French law, for the meetings to be quorate at the first attempt, at least 20% of the shareholders must vote on the ordinary resolutions and 25% of the shareholders must vote on the extraordinary resolutions. Shareholders are therefore strongly encouraged to submit their proxy votes either by post, email or vote electronically in accordance with the instructions in the notice convening the meeting, copies of which are available in the General Meetings section on the Company's website at www.novacyt.com/investors.

 

Following registration and proof of shareholding, shareholders will be able to virtually attend the AGM and vote online during the meeting if they wish. Following the meeting, a recording of the AGM will be available on the Company's website at www.novacyt.com/investors. Shareholders who have already voted (through a proxy, using the AGM or Votaccess portals) will be allowed to attend the AGM but will not be able to vote twice.

 

- End -

 

Contacts

Novacyt SA

David Allmond, Chief Executive Officer

James McCarthy, Chief Financial Officer

+44 (0)1276 600081

 

SP Angel Corporate Finance LLP (Nominated Adviser and Broker)

Matthew Johnson / Charlie Bouverat (Corporate Finance)

Vadim Alexandre / Rob Rees (Corporate Broking)

+44 (0)20 3470 0470

 

Numis Securities Limited (Joint Broker)

Freddie Barnfield / James Black / Duncan Monteith

+44 (0)20 7260 1000

 

Allegra Finance (French Listing Sponsor)

Rémi Durgetto / Yannick Petit

+33 (1) 42 22 10 10

r.durgetto@allegrafinance.com; y.petit@allegrafinance.com

 

FTI Consulting (International)

Victoria Foster Mitchell / Alex Shaw

+44 (0)20 3727 1000

victoria.fostermitchell@fticonsulting.com / Alex.Shaw@fticonsulting.com  

 

FTI Consulting (France)

Arnaud de Cheffontaines

+33 (0)147 03 69 48

arnaud.decheffontaines@fticonsulting.com  

 

About Novacyt Group

The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company supplies an extensive range of high-quality assays and reagents worldwide. The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates.

 

For more information, please refer to the website: www.novacyt.com 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRABKBBBDBKBKAD
Date   Source Headline
14th Nov 20241:20 pmRNSFurther expansion of cost reduction programme
14th Nov 20247:00 amRNS-RLondon Vet Show: Launch of animal multiplex assays
1st Nov 202412:45 pmRNSLiquidity Agreement and Total Voting Rights
31st Oct 20247:00 amRNSDirectorate Change
17th Oct 20247:00 amRNSIVDR accreditation
8th Oct 202412:30 pmRNSClosure of IT-IS International
1st Oct 202412:30 pmRNSLiquidity Agreement and Total Voting Rights
26th Sep 20247:01 amRNSInterim Results
26th Sep 20247:00 amRNSDirectorate Change
20th Sep 20245:30 pmRNSRule 19.6(c) confirmation of post-offer intentions
17th Sep 20247:00 amRNS-RLaunch of new website
12th Sep 20247:00 amRNSNotice of Results
2nd Sep 20241:30 pmRNSLiquidity Agreement and Total Voting Rights
22nd Aug 202411:30 amRNSSuccessful VAT reclaim of £12.2 million
1st Aug 20242:00 pmRNSLiquidity Agreement and Total Voting Rights
25th Jul 20247:00 amRNSHalf Year Trading Update
18th Jul 20244:00 pmRNSResult of AGM
18th Jul 20247:00 amRNSAGM Statement on Impact of DHSC Settlement
1st Jul 20243:45 pmRNSLiquidity Agreement and Total Voting Rights
26th Jun 20242:30 pmRNSNotice of rescheduled AGM
14th Jun 20247:00 amRNSPublication of Annual Report
11th Jun 20247:00 amRNSSettlement of the dispute with the DHSC
3rd Jun 20241:00 pmRNSLiquidity Agreement and Total Voting Rights
3rd Jun 20247:00 amRNSAGM voting
30th May 20247:00 amRNSFinal Results
20th May 20247:00 amRNSNotice of Results and AGM
2nd May 20243:45 pmRNSLiquidity Agreement and Total Voting Rights
1st May 20247:00 amRNSDHSC application for summary judgment dismissed
23rd Apr 20247:00 amRNSLong Term Incentive Plan
19th Apr 20247:00 amRNSDHSC Claim update – Pre-Trial Review
11th Apr 20247:00 amRNSDirectorate Changes and FY 23 results update
2nd Apr 20244:00 pmRNSLiquidity Agreement and Total Voting Rights
1st Mar 202412:30 pmRNSLiquidity Agreement and Total Voting Rights
6th Feb 20247:00 amRNSUpdate on Taiwanese divestment
1st Feb 20241:00 pmRNSLiquidity Agreement and Total Voting Rights
25th Jan 20247:00 amRNSTrading update
3rd Jan 202411:00 amRNSLiquidity Agreement and Total Voting Rights
2nd Jan 20247:00 amRNSAppointment of CFO
21st Dec 20237:00 amRNSUpdate on Taiwan laboratory disposal
1st Dec 202311:45 amRNSLiquidity Agreement and Total Voting Rights
7th Nov 20237:00 amRNSIVDR certification for DPYD genotyping assay
1st Nov 20232:30 pmRNSLiquidity Agreement and Total Voting Rights
26th Oct 20233:20 pmRNSResult of AGM
11th Oct 20237:00 amRNSAGM voting
5th Oct 20232:15 pmRNSNotice of rescheduled AGM
2nd Oct 20231:30 pmRNSLiquidity Agreement and Total Voting Rights
28th Sep 20233:15 pmRNSReminder to shareholders re. AGM voting
28th Sep 20237:00 amRNS2023 Interim Results
14th Sep 20237:00 amRNSAGM voting
13th Sep 20237:00 amRNSNotice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.